US Pharma MarketingSanofi asks to pull Tzield bid from FDA's controversial CNPV program: report
Since it was established nearly a year ago by the FDA, the Commissioner’s National Priority Voucher (CNPV) program has been steeped in controversy as a potential tool for government officials to cu The FDA's Commissioner's National Priority Voucher program has been steeped in controversy since its inception. Now, Sanofi has asked that one of its applications be taken out of the fast-track program, according to Stat. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards…
The FDA's Commissioner's National Priority Voucher program has been steeped in controversy since its inception. Now, Sanofi has asked that one of its applications be taken out of the fast-track program, according to Stat.
Source: FiercePharma